Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation
Standard
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation. / Auner, H W; Szydlo, R; van Biezen, A; Iacobelli, S; Gahrton, G; Milpied, N; Volin, L; Janssen, J; Nguyen Quoc, S; Michallet, M; Schoemans, H; El Cheikh, J; Petersen, E; Guilhot, F; Schönland, S; Ahlberg, L; Morris, C; Garderet, L; de Witte, T; Kröger, N; Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
in: BONE MARROW TRANSPL, Jahrgang 48, Nr. 11, 01.11.2013, S. 1395-400.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation
AU - Auner, H W
AU - Szydlo, R
AU - van Biezen, A
AU - Iacobelli, S
AU - Gahrton, G
AU - Milpied, N
AU - Volin, L
AU - Janssen, J
AU - Nguyen Quoc, S
AU - Michallet, M
AU - Schoemans, H
AU - El Cheikh, J
AU - Petersen, E
AU - Guilhot, F
AU - Schönland, S
AU - Ahlberg, L
AU - Morris, C
AU - Garderet, L
AU - de Witte, T
AU - Kröger, N
AU - Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
PY - 2013/11/1
Y1 - 2013/11/1
N2 - Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior autologous (auto)-SCT are not well defined. We performed an analysis of 413 MM patients who received a related or unrelated RIC allo-SCT for the treatment of relapse/progression after prior auto-SCT. Median age at RIC allo-SCT was 54.1 years, and 44.6% of patients had undergone two or more prior auto-SCTs. Median OS and PFS from the time of RIC allo-SCT for the entire population were 24.7 and 9.6 months, respectively. Cumulative non-relapse mortality (NRM) at 1 year was 21.5%. In multivariate analysis, CMV seronegativity of both patient and donor was associated with significantly better PFS, OS and NRM. Patient-donor gender mismatch was associated with better PFS, fewer than two prior auto-SCT was associated with better OS, and shorter time from the first auto-SCT to the RIC allo-SCT was associated with lower NRM. The results of this study identify patient and donor CMV seronegativity as the key prognostic factor for outcome after RIC allo-SCT for MM relapsing or progressing after prior auto-SCT.
AB - Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior autologous (auto)-SCT are not well defined. We performed an analysis of 413 MM patients who received a related or unrelated RIC allo-SCT for the treatment of relapse/progression after prior auto-SCT. Median age at RIC allo-SCT was 54.1 years, and 44.6% of patients had undergone two or more prior auto-SCTs. Median OS and PFS from the time of RIC allo-SCT for the entire population were 24.7 and 9.6 months, respectively. Cumulative non-relapse mortality (NRM) at 1 year was 21.5%. In multivariate analysis, CMV seronegativity of both patient and donor was associated with significantly better PFS, OS and NRM. Patient-donor gender mismatch was associated with better PFS, fewer than two prior auto-SCT was associated with better OS, and shorter time from the first auto-SCT to the RIC allo-SCT was associated with lower NRM. The results of this study identify patient and donor CMV seronegativity as the key prognostic factor for outcome after RIC allo-SCT for MM relapsing or progressing after prior auto-SCT.
KW - Adult
KW - Aged
KW - Female
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Male
KW - Middle Aged
KW - Multiple Myeloma
KW - Prognosis
KW - Recurrence
KW - Treatment Outcome
KW - Young Adult
U2 - 10.1038/bmt.2013.73
DO - 10.1038/bmt.2013.73
M3 - SCORING: Journal article
C2 - 23708704
VL - 48
SP - 1395
EP - 1400
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 11
ER -